Related Experiment Videos
Is there a treatment necessity for lipid disorders of uremic patients?
Insights
Lipid disturbances accelerate atherosclerosis in hemodialysis patients. Correcting abnormal lipoprotein metabolism may reduce ischemic vascular events in uremic individuals.
Area of Science:
- Nephrology
- Cardiovascular Medicine
- Biochemistry
Background:
- Uremic patients on long-term hemodialysis exhibit significant lipid disturbances.
- These lipid alterations are implicated as a key risk factor in atherosclerosis development and progression.
Purpose of the Study:
- To evaluate the role of lipid disturbances in the pathogenesis and acceleration of atherosclerosis in hemodialysis patients.
- To explore the potential of correcting abnormal lipoprotein metabolism to mitigate ischemic vascular events.
Main Methods:
- Review of existing literature on lipid profiles in uremic patients undergoing hemodialysis.
- Analysis of the impact of altered high-density lipoprotein (HDL) and very-low-density lipoprotein (VLDL) composition on atherogenesis.
Main Results:
- Altered HDL composition, specifically decreased HDL cholesterol with normal apoprotein AI, is relevant to the atherogenetic process.
- Accumulation of cholesterol-rich VLDL and intermediate-density lipoproteins (IDL) significantly contributes to atherosclerosis.
Conclusions:
- Lipid disturbances are a critical factor in atherosclerosis in hemodialysis patients.
- Further investigation is warranted to test the hypothesis that correcting abnormal triglyceride-rich lipoprotein catabolism can decrease ischemic vascular events.
Abstract:
In the present review, the role of lipid disturbances is evaluated as a risk factor in the pathogenesis and the potential acceleration of atherosclerosis in uremic patients undergoing long-term hemodialysis. The alteration in high density lipoprotein composition with a decrease in high density lipoprotein cholesterol but a normal apoprotein AI content may have relevance to the atherogenetic process. Moreover, the accumulation of cholesterol-rich, very low density lipoproteins and intermediate density lipoproteins may play a major role in atherosclerosis since these degradation products of triglyceride-rich particles are considered as atherogenic. The hypothesis should be tested whether a correction of the abnormal catabolism of triglyceride-rich lipoproteins in uremic patients leads to a decrease in ischemic vascular events.